Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Date:12/12/2012

RARITAN, N.J., Dec. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes.

Canagliflozin is an investigational, oral medication for the treatment of adult patients with type 2 diabetes. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to people without diabetes, which may contribute to elevated glucose levels. Canagliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

Metformin is a first-line pharmacotherapy that can be used alone or with other medications, including insulin, to treat type 2 diabetes. In people with type 2 diabetes, the liver overproduces glucose, which increases blood glucose levels. Metformin lowers blood glucose levels by decreasing the amount of glucose made by the liver.

If approved, this canagliflozin/metformin fixed-dose combination therapy could provide convenience for patients who may benefit from two diabetes medications working in one pill.

A significant portion of the clinical data in this NDA are derived from the comprehensive global Phase 3 clinical development program for canagliflozin, which were included in the NDA submitted to the FDA on May 31, 2012. The canagliflozin Phase 3 program represents the largest late-stage development program for an investigational pharmacologic product for the treatment of patients with type 2 diabetes submitted to health authorities to date.

The Phase 3 program evaluated the safety and efficacy of canagliflozin across the sp
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... on Thursday, August 7, 2014 at 11:00 AM Eastern ... ended June 30, 2014 and to provide a business ... second quarter conference call may be accessed by dialing ...
(Date:7/29/2014)... -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of ... that cause serious infections and diseases, announced today that ... Company,s stock, the NYSE MKT (the "Exchange") has contacted ... Company stated that its policy is not to comment ... Inc. Synthetic Biologics, Inc. (NYSE MKT: SYN) ...
(Date:7/29/2014)... -- ISPE—the International Society for Pharmaceutical Engineering announced ... as President and CEO, succeeding Nancy Berg ... last fall.  Mr. Bournas takes the helm at ... industry as well as significant international experience.  He ... the expansion of its global initiatives and business ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3
(Date:7/29/2014)... July 29, 2014 Winter is here ... Thursday afternoon in Sydney’s central business district. That is, ... Maori costume transformed the otherwise ordinary day into a ... singers are ardent advocates of The Truth About Drugs, ... of Scientology . They woke up the city with ...
(Date:7/29/2014)... Daily Gossip writes in its Fibroids Miracle review that ... teach users how to permanently eliminate uterine fibroids. The system ... over the world. , They have been able to ... quickly as 12 hours. This means that pain and other ... The Fibroids Miracle review also indicates that the method was ...
(Date:7/29/2014)... 29, 2014 Daily Gossip indicates in its ... tips to gain beautiful and clear skin in just 30 ... see these positive results even sooner than that. The new ... who used this step by step program, too. , ... for years. Mike battled this condition for a decade and ...
(Date:7/29/2014)... procedures using stem cells are running far ahead of ... a review in the August issue of ... journal of the American Society of Plastic Surgeons ... the marketplace is saturated with unsubstantiated and sometimes fraudulent ... Michael T. Longaker of Stanford University Medical Center and ...
(Date:7/29/2014)... 2014 As the Ebola outbreak in Liberia ... to both purchase critical emergency supplies locally, as well as ... These supplies will contain materials used to control the spread ... areas of the country. , With a large programmatic ... to the Ebola outbreak in the region. The current epidemic ...
Breaking Medicine News(10 mins):Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Amanda Leto’s Fibroids Miracle Review Reveals Clinically Proven Uterine Fibroids Cure System 2Health News:Acne No More Review Reveals Most Effective Acne Cure Program 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3
... Smart for Life(TM), the all-natural weight management program, opened in ... The Raimondo family began their weight-loss journey on the Smart ... of 235 lbs. for 6 family members. As friends and ... Raimondo envisioned an exciting business opportunity. , "Smart ...
... Haemonetics Corporation (NYSE: HAE ) will announce its ... release and 10:00 am (EST) webcast. , Webcast Link: ... from November 2, 2009 after 1:00 pm to November 9, ... Julie Fallon, Tel. (781) 356-9517, ...
... (Nasdaq: JMBA ) - As a part of their ... will be bringing some unexpected feel good boosts into people,s ... and Golden State visitors to free cable car rides this ... Jambassador, will bring unexpected cheer to riders as he makes ...
... ... ... has recently been promoted to Senior Vice President of Operations at Jackson & Coker ... , , , , ,"This position has been vacant for a while and ...
... ... announced the launch of their "Tats for Tatas" fundraising campaign that will ... In the company,s concerted efforts to raise awareness and funds for ... In addition, the company will be donating 10% of all proceeds from ...
... ... book Knockout: Interviews with Doctors Who are Curing Cancer and How to Prevent Getting It ... ... eight medical doctors featured in Suzanne Somers’ new book Knockout: Interviews with Doctors Who are ...
Cached Medicine News:Health News:Smart for Life(TM) Center Opens in Ottawa 2Health News:Surprise! Jamba Juice Treats Lucky San Francisco Cable Car Passengers to Free Rides on Saturday, October 17 2Health News:Surprise! Jamba Juice Treats Lucky San Francisco Cable Car Passengers to Free Rides on Saturday, October 17 3Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:Atomic Tattoos Announces "Tats for Tatas" October Fundraising Event to Benefit Local Breast Cancer Research 2Health News:Suzanne Somers Highlights Dr. Stephen Sinatra in Chapter for New Cancer Book 2
... The MicroTouch LP (low profile) is ... with a fixed fluoroscopy/x-ray gantry. The MicroTouch ... opposite the gantry and allows the user ... fluoroscopy ,and x-ray without loss of ...
Floor stand stabilizer system...
The robust, easy to maneuver floor-mounted stepper/stabilizer, offers strength and stability that has made this unit one of the most widely accepted floor fixation devices in the industry....
... of a welded titanium capsule containing either ... beads. The capsule body also contains ... x-ray markers to identify the source location ... non-sterile when shipped and must be sterilized ...
Medicine Products: